Last updated on April 18, 2014 at 15:19 EDT

China Botanic Announces Development of New Siberian Ginseng Polysaccharide Extract Powder

December 13, 2011

HARBIN, China, Dec. 13, 2011 /PRNewswire-Asia/ — China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) (“China Botanic” or the “Company”), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines (“TCM”) in China, today announced that the Company has successfully developed a new Siberian Ginseng (Acanthopanax) Polysaccharide Extract Powder (“Extract Powder”) and was also awarded the Scientific and Technological Achievements Appraisal Certificate (“Appraisal Certificate”) by the Science and Technology Bureau of Heilongjiang Province.

The Siberian Ginseng (Acanthopanax) Polysaccharide Extract Powder is an all-natural substance extracted from the stem of Siberian Ginseng utilizing proprietary extraction technology developed by the China Botanic research team. The Company’s Extract Powder technology was developed using its patented process of separating and extracting effective parts of the Siberian Ginseng (China Patent Number: ZL200710301682X), which was granted by the State Intellectual Property Office of the People’s Republic of China in June 2011.

According to pharmacological research, Siberian Ginseng Extract Powder contains strong immunogenic and antitumor properties with minimal side effects. The Company’s management estimates a significant market potential for Extract Powder based products, such as Siberian Ginseng Polysaccharide Extract Powder tablets and capsules. The Company plans to gradually launch its Extract Powder products in the market in 2012.

“We are pleased with efforts of our research and development team in developing the Acanthopanax Polysaccharide Extract Powder technology, which enables us to strengthen our market position as a leading supplier of Siberian Ginseng based products. We are confident in our ability to deliver high-quality Extract Powder products and are excited about the market opportunity in this category,” commented Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. “The successful development of Extract Powder technology marks an important achievement for China Botanic and we believe these new Siberian Ginseng products will make a valuable contribution to our revenue growth and profitability in the future.”


China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines (“TCM”), in the People’s Republic of China. All of the Company’s products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon managements beliefs, assumptions and expectations of the Companys future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Companys ability to manage expansion of its operations effectively, and other factors detailed in the Companys annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    Company Contact:                   CCG Investor Relations:
    China Botanic Pharmaceutical Inc.  Mr. Mark Collinson, Partner
                                        Phone: +1-310-954-1343 (Los
    Ms. Portia Tan, IR Contact          Angeles)
    Tel: 86-451-8260-2162               mark.collinson@ccgir.com
    Email: ir@renhuang.com             Website: www.ccgirasia.com

                                        Mr. Crocker Coulson,
                                        Phone: +1-646-213-1915 (New

SOURCE China Botanic Pharmaceutical Inc.

Source: PR Newswire